title: Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.
abstract: Widespread tumor genotyping has increased the complexity of lung cancer care, often identifying mutations of uncertain clinical significance. In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib sensitivity to develop a publicly accessible database to inform patient care.
authors: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
authors: Geoffrey R
authors: GR
authors: Oxnard
authors: Pasi A
authors: PA
authors: Jänne
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
references: J Thorac Oncol. 2012 Jun;7(6):1049-52
references: 22588155
references: J Thorac Oncol. 2009 Aug;4(8):994-1001
references: 19633474
references: Clin Cancer Res. 2012 Mar 15;18(6):1790-7
references: 22190593
references: Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7
references: 19906727
references: J Thorac Oncol. 2013 Feb;8(2):179-84
references: 23328547
references: Clin Cancer Res. 2013 Apr 1;19(7):1894-901
references: 23344264
references: Clin Cancer Res. 2011 Jun 1;17(11):3812-21
references: 21531810
references: Clin Cancer Res. 2012 Jun 15;18(12):3470-7
references: 22510346
references: J Clin Oncol. 2011 Aug 20;29(24):3316-21
references: 21788562